in treatment of mice with subcutaneous and orthotropic HCC. Induction of IDO RNA in tumor cells was evaluated by quantitative polymerase chain reaction (qPCR). Results: Combination therapy with 1-D-MT and an anti-CTLA-4 blocking antibody produces a greater anti-tumor effect in both a subcutaneous and orthotropic model than either drug alone. Additionally, tumors with high IDO induction showed a better response to combination treatment. Mice injected with anti-CTLA-4 antibody showed higher IDO2 expression in tumors. Conclusion: These results provide evidence that IDO expression induces an additional effect of immunosuppression in the tumor microenvironment, especially after anti-CTLA-4 therapy, and support a combination therapy with IDO inhibitors for a successful immunotherapy treatment.
* Corresponding author. Jay Idrees, The Ohio State University, USA Background: Costs and outcomes associated with liver resection alone (LR) versus simultaneous liver + colon resection(LR + C) are poorly defined. We sought to determine incremental costs and compare perioperative outcomes of LR versus LR + C among patients with colorectal liver metastasis (CRLM) Methods: The Nationwide Inpatient Sample (NIS) was used to identify 50,397 patients who underwent hepatectomy between 2002 and 2011 for CRLM. LR + C was performed in 3,399 (6.7%) patients. After propensity score matching, costs and outcomes were assessed among 2,336 patients who underwent LR + C vs. LR.
Results: Overall incidence of major complication was comparable among patients underlgoing LR + C versus LR (2.2% vs. 2.3%, respectively; p = 0.64). The incidence of certain complications was higher among patients who underwent LR + C vs. LR including sepsis (2.1% vs. 0.5%) and surgical site infection (5.5% vs. 10.4%) (both p < 0.001). Mortality was slightly higher among patients who underwent LR + C versus LR (2.3% vs. 1.4%; p < 0.001). Length-of-stay (LOS) was also longer among LR + C patients by an average of 2 days (p < 0.001). Incremental costs associated with a concomitant colon resection were $+6,335 (95%CI $4,644e$8,026). Additional costs were partially attributable to LOS (cost of each LOS day: $+1,821) (p < 0.001). In addition, among patients who experienced at least one major complication, the incremental cost was $+11,537 (95%CI $5,821e $17,253;p < 0.001). Factors associated with higher overall cost of LR + C included hospital volume, hospital teaching status, advanced liver disease, and the occurrence of major complication (all p < 0.001)( Figure) . Conclusion: Concomitant LR + C was associated with a slightly higher incidence of complications including sepsis and infection, as well as mortality. Costs associated with LR + C versus LR were modestly higher, yet increased significantly in the setting of a complication MO 40 SUPERUSERS OF POSTOPERATIVE HEPATOBILIARY CARE: IDENTIFYING DRIVERS OF EXTREME HEALTHCARE COSTS USING THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM S. A. Brownlee, L. A. Gil, A. N. Cobb, A. N. Kothari and G. J. Abood
